1. Home
  2. ANIX vs RSSS Comparison

ANIX vs RSSS Comparison

Compare ANIX & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.72

Market Cap

88.8M

Sector

Health Care

ML Signal

HOLD

Logo Research Solutions Inc

RSSS

Research Solutions Inc

HOLD

Current Price

$2.27

Market Cap

86.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
RSSS
Founded
1982
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
88.8M
86.5M
IPO Year
2013
2008

Fundamental Metrics

Financial Performance
Metric
ANIX
RSSS
Price
$2.72
$2.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$8.67
$5.00
AVG Volume (30 Days)
94.4K
102.7K
Earning Date
05-27-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
130.77
EPS
N/A
0.07
Revenue
$210,000.00
$28,793,922.00
Revenue This Year
N/A
$1.81
Revenue Next Year
N/A
$5.73
P/E Ratio
N/A
$31.07
Revenue Growth
N/A
2.77
52 Week Low
$2.44
$2.00
52 Week High
$5.46
$4.12

Technical Indicators

Market Signals
Indicator
ANIX
RSSS
Relative Strength Index (RSI) 42.94 41.37
Support Level $2.65 $2.16
Resistance Level $3.12 $2.66
Average True Range (ATR) 0.12 0.14
MACD -0.02 -0.02
Stochastic Oscillator 28.21 27.39

Price Performance

Historical Comparison
ANIX
RSSS

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About RSSS Research Solutions Inc

Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.

Share on Social Networks: